Carbaglu regulatory update

FDA approved an NDA from Recordati for Carbaglu carglumic acid to treat hyperammonemia due to hepatic enzyme N-acetylglutamate synthetase (NAGS) deficiency, an inherited disorder that causes ammonia t...